Cocrystal Pharma Inc Aktie News

Bisher keine schwerwiegenden unerwünschten Ereignisse berichtet Vorläufige Wirksamkeitsergebnisse werden Ende 2026 oder Anfang 2027 erwartet MIAMI, Fla. und BOTHELL, Wash.

BOTHELL, Wash., 17. Aug. 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" oder das "Unternehmen"), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das neuartige Therapeutika zur Deckung des weltweit wachsenden Bedarfs an wirksamen, sicheren antiviralen Behandlungen entwickelt, gab heute die Berufung von Carol Brosgart, MD, in seinen Vorstand bekannt,...

Langjähriger Investor OPKO Health erhöht seine Beteiligung, während Cocrystal auf Phase-1b-Daten zu Norovirus Ende 2026 zusteuert. BOTHELL, Wash., 03. Aug. 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" oder das "Unternehmen"), ein Biotechnologieunternehmen, das neuartige antivirale Therapeutika entwickelt, gab heute eine Investition in Höhe von $5 Mio. von OPKO Hea...

BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of...

Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq...

BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three months ended March 31, 2026.

BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled “...

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact BOTHELL, Wash., April 02, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the U.S. Food and Drug Administrat...